Advicenne's 2025 Financial Overview: Mixed Results and Future Prospects

Pharmaceutical company Advicenne reported an 18.7% rise in product sales in 2025, totaling €5.8 million, driven mainly by Sibnayal®, which rose by almost 37%. European end-market sales of Sibnayal® jumped over 71% to nearly €11 million, while royalties doubled to over €1.1 million. Despite these gains, the company faced a net loss of €9.53 million, up from €6.46 million in 2024, largely influenced by pharmaceutical taxes in France and financial restructuring costs.

Advicenne's cash position stands at €1.35 million, with funds expected to last until mid-Q2 2026. The company focuses on ensuring FDA approval for Sibnayal® in the U.S., anticipated in September 2026, while expanding sales in Europe and the Gulf countries.

CEO Didier Laurens mentioned the need to extend cash beyond Q2 2026 and expressed intentions to engage in strategic partnerships to enhance shareholder value.